ONCAlert | Upfront Therapy for mRCC
Videos  >  

Rationale for Using TAS-102 in Patients With Gastric Cancer

Hendrik-Tobias Arkenau, MD, PhD
Published Online:4:14 PM, Fri November 2, 2018


Hendrik-Tobias Arkenau, MD, PhD, executive medical director, executive medical director for Sarah Cannon Research Institute UK, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

Arkenau emphasizes that gastric cancers are one of the most common cancers worldwide and are related to both the third and fifth most common cancers. TAS-102 has shown good clinical evidence in patients with colorectal cancer and patients with gastric or gastroesophageal cancer.

The phase III TAGS study is investigating TAS-102 in patients with metastatic gastric cancer who have received more than 2 lines of treatment, he explains.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.